HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Psoriasis — Clinical Guidelines

Overview

Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by erythematous, scaly plaques. It affects approximately 2% of the global population and significantly impacts patients' quality of life due to both physical symptoms and psychological distress such as depression 11. Beyond its dermatological manifestations, psoriasis is increasingly recognized as a systemic condition associated with an elevated risk of cardiovascular diseases, including acute myocardial infarction (AMI), atherosclerosis, and degenerative valvular heart disease 1 2 5 14. This comorbidity necessitates a holistic approach to patient care, integrating dermatological and cardiovascular management strategies. Understanding these associations is crucial for clinicians to mitigate long-term cardiovascular risks in psoriasis patients, thereby improving overall patient outcomes in day-to-day practice 1 2 14.

Pathophysiology

Psoriasis involves a complex interplay of genetic predispositions and environmental factors that trigger an aberrant immune response, primarily driven by T-helper 1 (Th1) and Th17 cells 20. These immune cells activate a cascade of inflammatory cytokines, including TNF-α, IL-12/23, IL-17, and IL-23, which contribute to keratinocyte hyperproliferation and the characteristic skin lesions 2 20. The chronic inflammation seen in psoriasis extends beyond the skin, affecting systemic pathways that underpin cardiovascular disease development. For instance, systemic inflammation promotes endothelial dysfunction, characterized by increased vascular permeability and impaired nitric oxide bioavailability, facilitating atherosclerosis 1 5. Additionally, shared inflammatory mediators like ESAM (endothelial cell-selective adhesion molecule) and IL-16 play intermediary roles in linking psoriasis to cardiovascular complications such as AMI 1. These molecular mechanisms underscore the systemic nature of psoriasis and its potential to exacerbate cardiovascular risks through overlapping inflammatory pathways 4 9.

Epidemiology

Psoriasis affects approximately 2% of the global population, with a higher prevalence observed in certain ethnic groups and varying geographic distributions 11. The condition typically manifests between the ages of 15 and 35, although it can occur at any age 11. Males and females are equally affected, although some studies suggest a slight male predominance in severe cases 11. Epidemiological data indicate that the risk of cardiovascular diseases, including AMI, stroke, and atherosclerosis, is significantly elevated in psoriasis patients compared to the general population 1 2 14 18. Over time, there is a growing recognition of the increased cardiovascular burden in psoriasis, with trends showing a higher incidence of cardiovascular events in patients with longer disease duration and more severe psoriasis 3 18. These trends highlight the importance of early intervention and continuous monitoring in managing cardiovascular risks associated with psoriasis 1 3 18.

Clinical Presentation

The clinical presentation of psoriasis primarily involves well-demarcated, erythematous, scaly plaques, commonly found on the elbows, knees, scalp, and trunk 20. Typical presentations include plaque psoriasis, guttate psoriasis (more common in children), and pustular forms, which can be severe and life-threatening 20. Red-flag features include extensive skin involvement, systemic symptoms like fever and chills (especially in pustular forms), and signs of psoriatic arthritis, such as joint pain and swelling 20. Patients may also report significant pruritus and psychological distress, including anxiety and depression, which can complicate the clinical picture 11. Transitioning to diagnosis, clinicians must consider these varied presentations to tailor appropriate investigations and management strategies 20.

Diagnosis

The diagnosis of psoriasis typically begins with a thorough clinical history and physical examination, focusing on characteristic skin lesions and associated symptoms 20. Specific diagnostic criteria include:

Clinical Criteria:

- Presence of well-defined, erythematous, scaly plaques. - Distribution patterns consistent with psoriasis (e.g., extensor surfaces, scalp, nails). - Nail changes such as pitting, onycholysis, or oil drop discoloration.

Laboratory Tests:

- Biopsy: Histopathological examination showing hyperkeratosis, parakeratosis, and elongation of rete ridges. - Blood Tests: Elevated ESR or CRP may indicate systemic inflammation but are not specific to psoriasis.

Differential Diagnosis:

- Atopic Dermatitis: Often presents with more diffuse erythema and less scaling. - Seborrheic Dermatitis: Typically affects seborrheic areas like the scalp and face with greasy scales. - Lichen Planus: Characterized by violaceous, polygonal plaques with Wickham's striae. - Drug Eruption: History of recent medication use should be considered.

(Evidence: Expert opinion based on clinical guidelines and consensus)

Management

First-Line Treatment

Topical Agents:

- Corticosteroids: Hydrocortisone 1% cream, betamethasone dipropionate 0.05% ointment (applied bid-tid). - Vitamin D Analogues: Calcipotriol 0.005% ointment (applied bid). - Calcineurin Inhibitors: Tacrolimus 0.1% ointment (applied bid-tid).

Phototherapy:

- Narrowband UVB: 3 sessions per week, gradually increasing dose.

(Evidence: Moderate based on systematic reviews and clinical guidelines)

Second-Line Treatment

Systemic Agents:

- Methotrexate: 10-25 mg weekly dose, monitor liver function tests and CBC monthly. - Retinoids: Acitretin 25-50 mg daily, monitor lipid profile and liver function. - Cyclosporine: 2.5-4 mg/kg/day, monitor renal function and blood pressure.

(Evidence: Moderate based on randomized controlled trials and observational studies)

Refractory or Severe Cases

Biologics:

- TNF-α Inhibitors: Infliximab 5 mg/kg IV every 6-8 weeks, adalimumab 40 mg SC every 2 weeks. - IL-12/23 Inhibitors: Ustekinumab 90 mg IV every 12 weeks. - IL-17 Inhibitors: Secukinumab 300 mg SC monthly, ixekizumab 80 mg SC every 2-4 weeks. - IL-23 Inhibitors: Guselkumab 50 mg SC every 4 weeks.

Monitoring: Regular assessment of disease activity, adverse effects, and cardiovascular risk factors.

(Evidence: Strong based on randomized controlled trials and meta-analyses)

Complications

Cardiovascular Complications

Atherosclerosis and AMI: Increased risk due to systemic inflammation; monitor lipid profiles, blood pressure, and inflammatory markers regularly.

Degenerative Valvular Heart Disease: Higher incidence noted in psoriasis patients; echocardiographic surveillance recommended.

Other Complications

Psoriatic Arthritis: Joint pain, swelling, and functional impairment; regular rheumatologic evaluation.

Infections: Increased susceptibility due to immunosuppressive treatments; prophylactic measures and vigilance advised.

Management Triggers

Poorly Controlled Inflammation: Refractory psoriasis or inadequate treatment response.

Cardiovascular Risk Factors: Uncontrolled hypertension, hyperlipidemia, smoking, and obesity.

(Evidence: Moderate based on observational studies and cohort analyses)

Prognosis & Follow-Up

The prognosis of psoriasis varies widely depending on disease severity and response to treatment. Patients with mild psoriasis generally have a good prognosis, while those with severe psoriasis or significant comorbidities may face chronic challenges. Prognostic indicators include disease duration, extent of skin involvement, and presence of psoriatic arthritis or cardiovascular risk factors 18. Recommended follow-up intervals typically include:

Initial Follow-Up: Within 4-6 weeks post-treatment initiation to assess response and adjust therapy.

Routine Monitoring: Every 3-6 months to evaluate disease control, side effects, and cardiovascular risk factors.

Specialized Care: Referral to dermatology and cardiology specialists as needed, particularly for refractory cases or significant comorbidities.

(Evidence: Moderate based on clinical guidelines and observational studies)

Special Populations

Psoriasis in Specific Ethnic Groups

Hispanics: Higher prevalence of cardiovascular comorbidities; tailored cardiovascular risk assessment and management strategies are essential 10.

Pediatric Psoriasis

Management: Focus on topical therapies initially; systemic treatments considered cautiously based on disease severity and response 20.

Elderly Patients

Considerations: Increased risk of comorbidities; careful monitoring of drug interactions and organ function 20.

Comorbidities

Metabolic Syndrome: Aggressive management of cardiovascular risk factors alongside psoriasis treatment 8 16.

Psoriatic Arthritis: Integrated rheumatologic care alongside dermatologic management 20.

(Evidence: Moderate based on cohort studies and clinical guidelines)

Key Recommendations

Screen for Cardiovascular Risk Factors: Regularly assess and manage traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes) in psoriasis patients (Evidence: Strong 1 14).

Consider Biologic Therapy for Severe Psoriasis: Initiate biologic agents for patients with severe psoriasis refractory to conventional treatments to reduce systemic inflammation and cardiovascular risk (Evidence: Strong 21).

Monitor Inflammatory Markers: Regularly monitor inflammatory markers such as CRP and ESR to assess disease activity and cardiovascular risk (Evidence: Moderate 1 5).

Tailored Phototherapy: Use narrowband UVB phototherapy as a first-line option for moderate psoriasis, considering patient preference and accessibility (Evidence: Moderate 20).

Integrated Care Approach: Collaborate with cardiologists for patients with significant cardiovascular comorbidities to manage both psoriasis and cardiovascular risks effectively (Evidence: Moderate 1 18).

Educate Patients on Lifestyle Modifications: Encourage smoking cessation, healthy diet, regular exercise, and weight management to mitigate cardiovascular risks (Evidence: Moderate 11).

Regular Follow-Up: Schedule routine follow-ups every 3-6 months to reassess disease control and cardiovascular risk factors (Evidence: Moderate 18).

Evaluate for Psoriatic Arthritis: Screen for psoriatic arthritis in patients with skin manifestations, especially those with joint symptoms (Evidence: Moderate 20).

Consider Genetic and Epigenetic Factors: Be aware of potential genetic predispositions and epigenetic influences on disease severity and cardiovascular risk (Evidence: Weak 17).

Evaluate for Metabolic Syndrome: Screen for and manage metabolic syndrome components in psoriasis patients to reduce noncalcified coronary burden (Evidence: Moderate 8 16).

(Evidence levels inferred based on provided sources)

References

1 Kang X, Wang C, Zhong GQ, Zhang HJ. Endothelial selective adhesion molecule and interleukin-16 play an intermediary role in psoriasis complicated with acute myocardial infarction: A Mendelian randomization study. Medicine 2025. link 2 Yang Z, Li J, Song H, Mei Z, Zhang S, Wu H et al.. Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction. Scientific reports 2024. link 3 Zhou Q, Shi R. Shared Genetic Features of Psoriasis and Myocardial Infarction: Insights From a Weighted Gene Coexpression Network Analysis. Journal of the American Heart Association 2024. link 4 Song WJ, Oh S, Yoon HS. Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study. Journal of the American Academy of Dermatology 2025. link 5 Wang Z, Lv J, Zhao S, Yin Z, Shi W, Feng D et al.. Psoriasis and risk of new-onset degenerative valvular heart disease: a prospective cohort study. European heart journal. Quality of care & clinical outcomes 2025. link 6 Ohn J, Choi YG, Yun J, Jo SJ. Identifying patients with deteriorating generalized pustular psoriasis: Development of a prediction model. The Journal of dermatology 2022. link 7 Sioka C, Moulias C, Voulgari PV, Fotopoulos A, Bassukas ID. Single photon emission computed tomography myocardial perfusion imaging in patients with moderate to severe psoriosissis. Nuclear medicine review. Central & Eastern Europe 2021. link 8 Teklu M, Zhou W, Kapoor P, Patel N, Dey AK, Sorokin AV et al.. Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study. Journal of the American Academy of Dermatology 2021. link 9 Sajja A, Abdelrahman KM, Reddy AS, Dey AK, Uceda DE, Lateef SS et al.. Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time. JCI insight 2020. link 10 Nieves-Rivera J, Sulia C, Gonzalez R, Figueroa L, Banchs H, Altieri P et al.. Psoriasis and Coronary Artery Disease in Hispanics. Boletin de la Asociacion Medica de Puerto Rico 2016. link 11 Egeberg A. Psoriasis and comorbidities. Epidemiological studies. Danish medical journal 2016. link 12 Milaniuk S, Pietrzak A, Mosiewicz B, Mosiewicz J, Reich K. Influence of psoriasis on circulatory system function assessed in echocardiography. Archives of dermatological research 2015. link 13 Khalid U, Ahlehoff O, Gislason GH, Skov L, Torp-Pedersen C, Hansen PR. Increased risk of aortic valve stenosis in patients with psoriasis: a nationwide cohort study. European heart journal 2015. link 14 Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM et al.. Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. The Journal of investigative dermatology 2015. link 15 Mahajan VK, Khatri G, Prabha N, Abhinav C, Sharma V. Clopidogrel: a possible exacerbating factor for psoriasis. Indian journal of pharmacology 2014. link 16 Sunbul M, Agirbasli M. Psoriasis and atherosclerosis: Is there a need for novel biomarkers assessing cardiovascular risk?. Current pharmaceutical design 2014. link 17 Gupta Y, Möller S, Zillikens D, Boehncke WH, Ibrahim SM, Ludwig RJ. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Experimental dermatology 2013. link 18 Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B et al.. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology : JEADV 2013. link 19 Gullu H, Caliskan M, Dursun R, Ciftci O, Guven A, Muderrisoglu H. Impaired coronary microvascular function and its association with disease duration and inflammation in patients with psoriasis. Echocardiography (Mount Kisco, N.Y.) 2013. link 20 Raychaudhuri SP. A cutting edge overview: psoriatic disease. Clinical reviews in allergy & immunology 2013. link 21 Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. The British journal of dermatology 2011. link 22 Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. Journal of the American Academy of Dermatology 2011. link

Psoriasis